Anupam Rasayan India Ltd
Anupam Rasayan India Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards. - Majority of LOIs worth approx. Company targets a return to historical growth rates of 25-30%+ from FY '26 onwards.
From Anupam Rasayan India Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards.
- Majority of LOIs worth approx. INR14,600 crores will commercialize over 4-10 years, contributing ~INR2,000 crores annual incremental revenue over 2-3 years.
- New product ramp-ups, especially in Pharma (20%-25% of revenue in FY '26) and Polymer/Performance Chemicals (expected to rise to 25%+ revenue in FY '26), plus recovery in agrochemicals expected to drive volume growth.
- Agrochemical demand is rebounding with volume-led growth; new high-value AI molecules contribute significantly with triple-digit dollar per kg pricing.
- Volume, rather than price, is expected to drive growth; pricing impact is minimal.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anupam Rasayan India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No additional capex required for servicing the first 1,000 tons of demand for the new AI product; this will be met with current capacities.
- Potential capex will be considered only upon ramp-up or securing a take-or-pay contract for higher volumes.
- Current assets can support production worth INR60-70 crores annually for Elementium orders; possible debottlenecking can increase this to INR100 crores without major capex.
- For scaling Elementium's full potential (approx. $70-$90 million revenue p.a.), significant capex will be necessary.
- INR670 crores of planned capex completed, with two manufacturing facilities commercialized and one facility ready for commercialization imminently.
- Capex will focus on expanding production capacity to support next-phase growth and new molecule launches.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anupam Rasayan India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current order book stands at approximately INR 14,646 crores, spread over 4 to 10 years.
- Out of this, INR 3,100 crores worth of LOIs and contracts have already been commercialized.
- These commercialized orders contribute to over 20% of revenue in FY '25.
- Majority of the remaining LOIs and contracts are expected to be commercialized in FY '26.
- A significant LOI product in the agrochemical segment (an AI molecule) was signed in Q4 2022 and is currently ramping up, expected to contribute triple-digit million dollar revenue.
2 more points management made on order book & pipeline
Anupam Rasayan India Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹636 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anupam Rasayan's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q2 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Clean Science (Q4 FY25)
2,500 crores to Rs. Key concall takeaways from Clean Science's Q4 FY25 earnings call — and how it ranks against sector peers.
- Yasho Industries (Q4 FY25)
Exports continue to be a key revenue driver, contributing around 67% of total revenue. Key concall takeaways from Yasho Industries's Q4 FY25 earnings call…
- Vinati Organics Ltd (Q4 FY25)
Overall growth supported by strategic capex (~INR360 crores in FY26), innovation, and operational efficiencies. Key concall takeaways from Vinati Organics's Q4…
- PCBL Chemical (Q4 FY25)
Export sales volume for Carbon Black grew strongly by 16.8% in Q4 FY'25, reflecting strong international demand. Key concall takeaways from PCBL Chemical's Q4…
Frequently Asked Questions
What were Anupam Rasayan India Ltd Q4 FY25 results?
Company targets a return to historical revenue growth rates of 25%-30%+ from FY '26 onwards. - Majority of LOIs worth approx. Company targets a return to historical growth rates of 25-30%+ from FY '26 onwards.
What is Anupam Rasayan India Ltd share price analysis?
Anupam Rasayan India Ltd currently shows a neutral. The stock trades at a P/E of 81.4 with a market cap of ₹13,847 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anupam Rasayan India Ltd planning capital expenditure?
No additional capex required for servicing the first 1,000 tons of demand for the new AI product; this will be met with current capacities. - Potential capex will be considered only upon ramp-up or securing a take-or-pay contract for higher volumes. - Current assets can support production worth INR60-70 crores annually for Elementium orders; possible debottlenecking can increase this to INR100 crores without major capex. - For scaling Elementium's full potential (approx.
Keep Anupam Rasayan India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.